Amineptine

Structural formula
General
Non-proprietary name	Amineptine
other names	7 - [(10,11-dihydro-5 H -dibenzo [ a , d ] -cyclohepten-5-yl) amino] heptanoic acid ( IUPAC )
Molecular formula	C 22 H 27 NO 2
External identifiers / databases
CAS number 57574-09-1 (amineptine) 30272-08-3 ( hydrochloride ) 68946-01-0 ( sodium salt ) EC number 260-818-0 ECHA InfoCard 100.055.271 PubChem 34870 ChemSpider 32091 DrugBank DB04836 Wikidata Q44822059
Drug information
ATC code	N06 AA19
Drug class	antidepressant
properties
Molar mass	337.2 g · mol -1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed GHS hazard labeling no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Amineptine is an atypical tricyclic antidepressant that selectively inhibits the reuptake of dopamine and norepinephrine . It was introduced in 1978 by the French pharmaceutical company Servier under the trade name Survector (also known as Maneon in Italy). Since amineptine is predominantly dopaminergic, the mood is lightened much faster than with conventional antidepressants, which are mainly serotonergic and / or noradrenergic. The highly euphoric and stimulating effects have also led to some cases of non-medicinal use. In 1999 the drug was voluntarily withdrawn from the market in France and Portugal due to its use as an intoxicant, its addiction potential and its hepatotoxicity . As a result, worldwide production was completely stopped in 2005.

Therapeutic indications

Amineptine was originally developed to treat major depression . It has also been used off-label for Parkinson's disease and attention deficit / hyperactivity disorder (ADHD).

Mechanism of action

Amineptine causes a strong inhibition of the uptake of dopamine , an inhibition of the uptake of norepinephrine and also slightly anticholinergic and antihistamine effects.

Non-medical use

Amineptine, in combination with other drugs, has a clear potential for dependence . It develops with cocaine a cross-tolerance . Amineptine is used as a doping agent in sport .

Legal status

In the Federal Republic of Germany, amineptine is a marketable narcotic , but not a prescription drug, according to Annex II to Section 1, Paragraph 1 of the Narcotics Act. Possession without permission from the Federal Opium Agency at the Federal Institute for Drugs and Medical Devices is a criminal offense. Amineptine never came onto the market in Germany.

Individual evidence

1. ↑ External identifiers or database links for amineptine hydrochloride : CAS number: 30272-08-3, EC number: 250-107-3, ECHA InfoCard: 100.045.538 , PubChem : 44558536 , ChemSpider : 32090 , DrugBank : DB04836 , Wikidata : Q419643 .
2. ↑ External identifiers or database links for amineptine sodium : CAS number: 68946-01-0, PubChem : 71587238 , ChemSpider : 32698049 , Wikidata : Q27264462 .
3. ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
4. ↑ Docket No. 02N-0101. US Food and Drug Administration, April 9, 2002, accessed on January 30, 2014 (English): "In 1999, amineptine products were voluntarily removed from the market in France and Portugal due to risks of misuse and addiction." 
5. ↑ Docket No. 03N-0015. US Food and Drug Administration, February 3, 2003, accessed January 30, 2014 (English): "It has been withdrawn from the market in France, where the drug was developed a few decades ago, for reasons of considerable hepatotoxicity and abuse. " 
6. ^ Eve & Rave .
7. ^ Narcotics Act (Federal Law Gazette I 2001, 1187 - 1189), Annex II; November 14th, 2011. .

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !